ClinicalTrials.gg
CompletedNCT03844555Updated Aug 13, 2020

Elafibranor Pharmacokinetic Parameters in Renal Impaired Patients

A Phase 1 interventional study of Elafibranor in Renal Impairment, Renal Insufficiency and Kidney Diseases, sponsored by Genfit. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-08-13.

Sponsored by Genfit · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
23
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 107 studies in Renal Insufficiency with a site in France — 13 open to participants now, 16 under way, none of them phase 3. Renal Insufficiency · France.

Enrollment
57th of 67
23 · median 108
Started
2019
with 5 others
Phase 1
5 of 107
none open now
Registered
71st of 107
by date

Among the 107 studies in Renal Insufficiency with a site in France, this one is the 57th largest by enrollment of the 67 interventional ones that give a count, is one of 6 that started in 2019, is one of 5 in phase 1, and was the 71st registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 145 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

13 of the 107 studies in Renal Insufficiency with a site in France are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 91 Renal Insufficiency studies recruiting now, 48 (53%) set no upper age limit and 18 (20%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 107 studies in Renal Insufficiency with a site in France, or all of them as a file.
02

Study summary

This study is being conducted in order to assess the need for dose adjustment for elafibranor in participants with renal impairment. Pharmacokinetic parameters of elafibranor and its active metabolite (GFT1007) will be compared in severe renal impaired participants (eGFR\<15mL/mn/1.73m\^2) versus healthy participants after a single oral administration of elafibranor 120 mg

03

Conditions studied

  • Renal Impairment
  • Renal Insufficiency
  • Kidney Diseases
  • Pharmacokinetics
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For all participants

  1. Male or female subjects, aged 18 to 75 years inclusive;
  2. Females participating in this study must be of non- or using highly efficient for the full duration of the study
  3. Negative serum pregnancy test at screening (if applicable);
  4. Non-smoker subject or smoker of not more than 5 cigarettes a day;

    For Renally Impaired Participants

  5. ESRD patient not yet on dialysis with an estimated (eGFR) \<15mL/min/1.73m\^2;
  6. Documented renal impairment indicated by reduced eGFR within 12 months of screening or longer;
  7. Stable renal function as evidenced by ≤ 30 percent difference in two evaluation of eGFR on two separate occasions separated by at least 28 days with one measurement being the value at screening;
  8. (BMI) between 20 and 36 kg/m\^2 inclusive.

    For Healthy Volunteers with normal renal function:

  9. eGFR ≥ 90mL/min/1.73m\^2;
  10. No proteinuria (\< 0.15 g/L determined by urinalysis);
  11. Body Mass Index between 20 and 30 kg/m\^2 inclusive and body weight not lower than 55kg;
  12. Matched to at least 1 renal impaired patient by ethnic group, sex, age (+/- 10 years) and BMI (+/- 20 percent).

Other protocol-defined inclusion criteria may apply

Exclusion criteria

Exclusion Criteria:

All Participants

  1. Positive surface antigen or anti Virus antibody, or positive results for 1 or 2 tests;
  2. History or presence of drug or alcohol abuse (alcohol consumption > 40 grams/day);
  3. Blood donation (including in the frame of a clinical trial) within 2 months before administration or blood donation planned during the study or within 2 months following participation to the study;
  4. Participants who are pregnant or breastfeeding. Participants should not be enrolled if they plan to become pregnant during the time of study participation;
  5. Positive results of screening for drugs of abuse;
  6. Evidence or history of uncontrolled hematological, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, metabolic, systemic, infectious, or allergic disease (including drug or allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing);
  7. General anesthesia within 3 months before administration;
  8. Major surgery within 28 days prior to randomization or major surgery planned during the next 6 months.

    For Renally Impaired Participants:

  9. History of renal transplant;
  10. Evidence of an unstable clinically important medical condition other than impaired renal function;
  11. Acute exacerbation or unstable renal function, as indicated by worsening of clinical and/or laboratory signs of renal impairment, within the 4 weeks before study drug administration;
  12. Participants undergoing any method of dialysis or hemofiltration;
  13. Disorders or surgery of the gastrointestinal tract which may interfere with drug absorption or may otherwise influence the pharmacokinetics of the medicinal product (e.g., inflammatory bowel disease, resections of the small or large intestine, etc.);
  14. History of febrile illness within 5 days prior to dosing;
  15. Evidence of clinically significant liver disease or liver damage (e.g., hepatitis B or C, hepatitis, primary biliary cirrhosis, non-alcoholic fatty liver disease, elevated or alanine aminotransferase that is considered clinically significant by the Investigator, etc.). Presence or history of protein drug hypersensitivity, or allergic disease diagnosed and treated by a physician
  16. Any drug intake during the 2 weeks or 5 half-life of the drug preceding the first administration except those defined in the protocol

    For Healthy Volunteers with normal renal function:

  17. Any history or presence of renal disease
  18. Frequent headaches (> twice a month) and / or migraines, recurrent nausea and / or vomiting;
  19. Symptomatic hypotension whatever the decrease of blood pressure or asymptomatic postural hypotension defined by a decrease in Systolic Blood Pressure (≥20 mmHg) or Diastolic Blood Pressure (≥10 mmHg) within three minutes when changing from the supine to the standing position;
  20. Inability to abstain from intensive muscular effort;
  21. Any drug intake (except paracetamol 3g/d or ) during the 2 weeks or 5 half-life of the drug preceding the first administration;
  22. Subject who would receive more than 4500 euros as indemnities for his participation in biomedical research within the 12 last months, including the indemnities for the present study.

Other protocol-defined exclusion criteria may apply

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    End Stage Renal Disease

    Single oral dose of elafibranor 120mg

    Drug: Elafibranor

  • Experimental
    Healthy

    Single oral dose of elafibranor 120mg

    Drug: Elafibranor

Interventions

  • 120mg oral single dose

    Also known as: GFT505

06

What researchers measure

Primary outcomes

  1. Area under curve from dosing time to last measurement (AUC(0-t)) of elafibranor and active metabolite

    In participants with end stage renal disease compared to healthy volunteers

    Time frame: pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose

  2. Area under curve from dosing time to infinity (AUC(0-∞)) of elafibranor and active metabolite

    In participants with end stage renal disease compared to healthy volunteers

    Time frame: pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose

Secondary outcomes

  1. Plasma pharmacokinetics: maximum plasma drug concentration (Cmax)

    for elafibranor and metabolites

    Time frame: pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose

  2. Plasma pharmacokinetics: elimination half-life (t1/2)

    for elafibranor and metabolites

    Time frame: pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose

  3. Plasma pharmacokinetics: apparent volume of distribution (Vd/F)

    for elafibranor

    Time frame: pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose

  4. Plasma pharmacokinetics: renal clearance (CLr)

    for elafibranor and metabolites

    Time frame: pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose

  5. Plasma pharmacokinetics: apparent non renal clearance (CLnr/F)

    for elafibranor

    Time frame: pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose

  6. Plasma pharmacokinetics: apparent total clearance (CL/F)

    for elafibranor

    Time frame: pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose

  7. Plasma pharmacokinetics: area under the plasma concentration-time curve extrapolated from time t to infinity as a percentage of total area under the plasma concentration-time curve (%AUCextra)

    for elafibranor and metabolites

    Time frame: pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose

  8. Plasma pharmacokinetics: area under curve from dosing time to last measurement (AUC(0-t)) of glucuronide metabolites and corresponding aglycones

    for the glucuronide metabolites of elafibranor and corresponding aglycones

    Time frame: pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose

  9. Plasma pharmacokinetics: area under curve from dosing time to infinity (AUC(0-∞)) of glucuronide metabolites and corresponding aglycones

    for the glucuronide metabolites of elafibranor and corresponding aglycones

    Time frame: pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose

  10. Urine pharmacokinetics: amount excreted (Ae)

    for elafibranor and metabolites, if applicable. 24 hours urine collection from dosing to 216 hours post-dose

    Time frame: pre-dose and then 24, 48, 72, 96, 120, 144, 168, 192, 216 hours post-dose

  11. Urine pharmacokinetics: cumulative amount excreted (Ae0-t)

    for elafibranor and metabolites, if applicable. 24 hours urine collection from dosing to 216 hours post-dose

    Time frame: pre-dose and then 24, 48, 72, 96, 120, 144, 168, 192, 216 hours post-dose

  12. Urine pharmacokinetics: percentage of dose excreted (Fe)

    for elafibranor and metabolites, if applicable. 24 hours urine collection from dosing to 216 hours post-dose

    Time frame: pre-dose and then 24, 48, 72, 96, 120, 144, 168, 192, 216 hours post-dose

  13. Urine pharmacokinetics: cumulative percent of dose excreted (Fe0-t)

    for elafibranor and metabolites, if applicable. 24 hours urine collection from dosing to 216 hours post-dose

    Time frame: pre-dose and then 24, 48, 72, 96, 120, 144, 168, 192, 216 hours post-dose

  14. Urine pharmacokinetics: renal clearance (CLR)

    for elafibranor and metabolites, if applicable. 24 hours urine collection from dosing to 216 hours post-dose

    Time frame: pre-dose and then 24, 48, 72, 96, 120, 144, 168, 192, 216 hours post-dose

07

Study locations

2 sites
  • Eurofins Optimed
    Gières, 38610, France
  • ARENSIA Exploratory Medicine Unit, Nephrology Hospital Dr. Carol Davilla
    Bucharest, 010701, Romania
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2019 to primary completion in Mar 2020, 12 months.

Of 212 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 12 months is above that.

Counting every sponsor, half of 230 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2019
First posted
Feb 18, 2019
StartActual
Feb 28, 2019
Primary completionActual
Mar 15, 2020
CompletionActual
Mar 21, 2020
Last update
Aug 13, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03844555
Lead sponsor
Genfit
Responsible party
Sponsor
First posted
Feb 18, 2019
Start date
Feb 28, 2019
Primary completion
Mar 15, 2020
Completion
Mar 21, 2020
Last update
Aug 13, 2020

Study contacts

Pascal Birman, MD
study director · Genfit

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elifibranor

Start the discussion